Autosomal dominant type IIa hypercholesterolaemia (ADH) is characterised by an elevation of total plasma cholesterol associated with increased LDL particles. Numerous different molecular defects have been identified in the LDL receptor (LDLR) and few specific mutations in the apolipoprotein B (APOB) gene resulting in familial hypercholesterolaemia and familial defective apoB-100 respectively. To estimate the respective contribution of LDLR, APOB and other gene defects in this disease, we studied 33 well characterised French families diagnosed over at least three generations with ADH through the candidate gene approach. An estimation of the proportions performed with the HOMOG3R program showed that an LDLR gene defect was involved in approximately 50% of the families (P = 0.001). On the other hand, the estimated contribution of an APOB gene defect was only 15%. This low estimation of ADH due to an APOB gene defect is further strengthened by the existence of only two probands carrying the APOB (R3500Q) mutation in the sample. More importantly and surprisingly, 35% of the families in the sample were estimated to be linked to neither LDLR nor APOB genes. These data were confirmed by the exclusion of both genes through direct haplotyping in three families. Our results demonstrate that the relative contributions of LDLR and APOB gene defects to the disease are very different. Furthermore, our results also show that genetic heterogeneity is, generally, underestimated in ADH, and that at least three major groups of defects are involved. At this point, the contribution of the recently mapped FH3 gene to ADH cannot be assessed nor its importance in the group of 'non LDLR / non APOB' families.
Introduction
Type IIa hypercholesterolaemia is characterised (1) biologically, by an elevated concentration of plasma cholesterol, (2) clinically, by xanthomas, arcus corneae, and premature coronary heart disease, and (3) genetically, usually by a dominant mode of inheritance. 1 The elevation of total cholesterol (TC) is due to an increase of cholesterol bound to low density lipoprotein particles (LDL), above the 95th percentile cut-off for the general population.
It was generally assumed that autosomal dominant hypercholesterolaemia (ADH) is exclusively due to a defect either in the LDLR (low density lipoprotein receptor) or the APOB (apolipoprotein B) gene. The term familial hypercholesterolemia (FH) has been applied broadly to patients presenting with a mutation in the LDLR gene. This gene encodes a cell surface glycoprotein that mediates the removal from blood of cholesterol carrying LDL particles via apolipoprotein B.
1,2
The LDLR gene in 19p13 spans 45 kilobases and comprises 18 exons. 3 Over 500 different mutations have been reported. 4 However, individuals with elevated LDL cholesterol and normal LDL receptor activity have been reported as well as the absence of mutation in the LDLR gene of FH probands. 5 Furthermore, no mutations are found after systematic sequencing of the LDLR gene in about 15% of probands. 6, 7 Among the latter, some probands probably do not carry a mutation in this gene. Thus FH does not account for all familial cases of high LDL cholesterol levels. In hypercholesterolaemic patients, simultaneous measurement of turnover rates of autologous and normal homologous LDL demonstrated fractional clearance rates for autologous LDL that were significantly lower than those for normal homologous LDL. 8 By in vitro binding studies, Innerarity et al 9 demonstrated that in one case this reduced binding was the result of a defect in apolipoprotein B-100. Further studies of the APOB gene identified a single nucleotide substitution from G ® A, at nucleotide 10 699, which resulted in a glutamine for an arginine substitution at residue 3500 (R3500Q). 10 This molecular defect segregated in some families designated as presenting with familial defective apolipoprotein B-100 (FDB). This mutation was usually associated with the same haplotype, suggesting a common European ancestral mutation. 11, 12 Interestingly, a second hypercholesterolaemic mutation was described at the same codon resulting in a tryptophan for an arginine substitution APOB R3500W. 13 Finally, Pullinger et al 14 reported a third mutation which decreases LDL binding activity: the APOB 3531 (R3531C) mutation at nucleotide 10 800, which results in a cysteine for an arginine substitution. However, in more recent studies, this mutation was not found associated with hypercholesterolaemia and/or coronary artery disease. 15, 16 These mutations are the only reported defects of the APOB gene associated with hypercholesterolaemia. Finally, we recently reported on the mapping of a third major gene named FH3 at chromosome 1p34-p32, demonstrating the existence of further genetic heterogeneity for ADH. 17 The prevalence of monogenic hypercholesterolaemia in the general population has been determined on several occasions. Using the data from genetic analysis of hyperlipidaemia among consecutively studied survivors of myocardial infarction, Goldstein et al 18 estimated a minimal heterozygote frequency for familial forms of isolated hypercholesterolaemia of 1 in 500 individuals of the general population. Subsequently, molecular defects in the LDLR gene were identified. It was generally assumed that these defects accounted for all the heterozygous forms of hypercholesterolaemia and therefore the FH heterozygote frequency was considered identical to that previously estimated for monogenic hypercholesterolaemia (ie 1/500). However, genetic heterogeneity was demonstrated through the identification of FDB whose prevalence was estimated between 1/500 and 1/1000. 19, 20 These tests allowed us to estimate, in our sample, the proportion of families with an LDLR (α) or an APOB ( ) gene defect. Furthermore, they also demonstrated the existence of a third group of families (γ) associated with mutations within one, or several, different locus (i).
Materials and methods

Probands and families
Probands were ascertained among consecutive patients from lipid clinics belonging to four medical centres located either in the western or central parts of France or the Paris area. The following selection criteria were used: total and LDL cholesterol above the 95th percentile when compared with sex and age matched French populations, 28 triglycerides below 1.3 mmol/L, personal or documented familial xanthomas, and/or arcus corneae, and early coronary artery disease. Lipid measurements were repeated to ascertain the existence of primary type IIa hypercholesterolaemia. At the same time, family history and pedigrees were investigated. Forty-five probands matching the selection criteria and belonging to multiplex families displaying the disease over at least three generations were selected for the study. Family members were examined and their lipid levels repeatedly determined. Subsequently, only 36 families were selected (9 being eliminated because of existence of elevated triglyceride levels in some first-degree relatives, suggesting the possibility of familial combined hyperlipidaemia). Genetic analyses using multi-allelic markers from different chromosomal regions led to the exclusion of three families for non-paternity. Finally, a total of 252 subjects from 33 hypercholesterolaemic families (with a mean of 2.3 sibs and representing 172 meioses) was included in the study ( Figure 1 ). Probands (mean age around 49 years old) had mean total cholesterol of 10.15 ± 2.72 mmol/L and 7.29 ± 2.01 mmol/L, before and after hypocholesterolaemic treatment, respectively. Mean LDL cholesterol were 7.03 ± 1.91 mmol/L and 5.58 ± 2.01 mmol/L, before and after treatment, respectively. Mean triglycerides was 1.01 ± 0.29 mmol/L. Phenotypic status for family members was initially established by the recruiting team on each site and was independently and blindly confirmed by members from other teams. A bimodal distribution was observed for the standardised total cholesterol values of all first-degree relatives. A bimodal distribution was also observed for raw LDL-cholesterol values. Since this parameter is calculated and not directly measured, standardisation could not be performed. This explains the strong overlap observed in Figure 2 . Conversely, triglycerides values displayed an unimodal distribution similar to that of the normal population (data not shown). Finally arcus, corneae, myocardial infarction at early age, and xanthomas were variously observed among affected subjects in agreement with well documented variable expressivity in this disease.
LDLR gene analysis
Four biallelic polymorphisms of the LDLR gene were tested by PCR amplification: Taq1, BstEII, HincII, and AvaII located in introns 4 and 12 and in exons 12 and 13 respectively. 25, 29, 30 Four multi-allelic markers were also tested, a polymorphism associated with an Alu sequence located within intron 15, 31 a (CA) n (D19S394), a (TAA) n (D19S594) and a (TA) n repeat located respectively flanking, in intronic sequences and in the 3' end of the LDLR gene. 32, 33 The Alu sequence was amplified by PCR on a 9600 Geneamp (Perkin-Elmer Biosystems, Courtaboeuf, France) for 30 cycles (94°C for 20 s, 56°C for 20 s, 72°C for 30 s) with 20 mM of each primer, 1 mM MgCl 2 , and radiolabelled α 33 P dATP. PCR products were migrated on a 5% non-denaturing polyacrylamide gel at 20 V/cm, and then the gel was dried and exposed overnight on to autoradiographic film (Kodak, Paris, France). For the diand tri-nucleotide repeats, two volumes of dye containing 95% formamide were added to each amplification product before electrophoresis on 10% denaturing polyacrylamide gels at 40 V/cm. DNAs were transferred to a Hybond N + membrane (Amersham Pharmacia Biotech Europe, Orsay, France) and fixed in NaOH 0.4 M. Membranes were hybridised with 20 ng of one of the PCR primers, radiolabelled by a 3' tailing reaction (Boehringer, Mannheim, Germany), and incubated at 42°C for 3 h in phosphate buffer 0.13 M pH7, SDS 7%, NaCl 0.5 M and PEG 10%. 34 Membranes were washed and exposed to autoradiographic film for 4 to 10 hours. The (TA) n repeat was originally described as a triallelic marker (7, 8 , and 10 repeats). However, we have identified two other alleles with 11 and 12 repeats.
APOB gene analysis
The multiallelic 3'HVR 11 and the (TG) n repeat 35 were PCR amplified and their alleles were detected as described above. Running conditions for the 3'HVR marker were on a 4% denaturing acrylamide gel at 50 V/cm. An insertion/deletion polymorphism (SP) located in the signal peptide of the gene was PCR-amplified and run in an 8% non-denaturing polyacrylamide gel. 36 Screening for the R3500Q and R3531C mutations in the APOB gene were performed by PCRmediated site-directed mutagenesis followed by MspI and MluI digestions. Two bands of smaller molecular weight were observed when either mutation was present.
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Genetic studies
Pairwise lod scores were computed at 8 recombination fraction (Θ = 0.001, 0.005, 0.01, 0.02, 0.03, 0.04, 0.05, and 0.10) using the MLINK subprogram of the LINKAGE package (version 5.1). 38 Lod score analyses were performed with a complete or incomplete penetrance (1.0 or 0.9, respectively) for heterozygous individuals. The admixture estimation test 39 was performed using two HOMOG programs: HOMOG and HOMOG3R. 40 HOMOG computes likelihoods under the hypothesis of two family types, one with linkage and the other one without linkage to the locus tested and estimates the proportion of linked families. HOMOG3R calculates likelihoods under the assumption that a trait is linked to locus 1 (proportion α) in some families, and to locus 2 (proportion ) in other families on another chromosome, against the hypothesis that some families may be linked to another unidentified locus (proportion γ) and estimates the three proportions. We used this program HOMOG3R, where both loci are candidate genes and with lod scores evaluated at Θ = 0.001. Linkage homogeneity was also tested between families sampled in the Paris area and various centres from the western part of France. We used the following property of the maximum likelihood ratio test. When a given sample is divided into k subsamples, if L t is the maximum likelihood for the whole sample and L i the maximum likelihood for subsample i, then -2Ln(L t /Σ i L i ) asymptotically follows a 2 distribution with n(k-1) degrees of freedom, where n is the number of estimated independent parameters. In our case, the estimated parameters were α and since thetas were set at 0.001.
Results
Genetic analysis for the LDLR and APOB genes Molecular defects responsible for ADH have been identified in two genes: LDLR and APOB. To estimate their respective contribution to the disease, we recruited 33 families (252 individuals) with a compatible autosomal dominant transmission of this trait over three generations (Figure 1) . To evaluate the families linked to either LDLR or APOB genes, individuals were first haplotyped using polymorphic LDLR and APOB gene markers, respectively. Then a classic genetic linkage analysis was performed using the MLINK program. Because of the small size of many of the families, mostly exclusions could be definitively ascertained.
For the LDLR gene markers, linkage disequilibrium between different polymorphic markers considerably reduced the overall informativity at this locus. Therefore we increased the number of polymorphic markers tested to eight, resulting in 30 informative families out of 33 (Table 1): 1) linkage (lod score ³ 2.00 under the candidate gene approach) was reached in HC5 family;
2) an exclusion (lod score ² -2.00) could be definitely demonstrated in 23% (7/30) of the informative families (HC2, 6, 13, 32, 33, 47, and 70);
3) 20 families displayed small positive lod scores; and 4) two families displayed small negative lod scores These two groups included both linked and unlinked families but because of the size of the families the exclusion or linkage threshold could not be reached. 5) only three families remained non-informative (lod score = 0.00) because probands were homozygous for all tested markers (HC3, 31, and 36).
These results showed that at least 23% of the ADH families of the sample were not carrying an LDLR gene defect.
For the APOB locus, 30 families were informative (Table 1): 1) an exclusion was definitely demonstrated in 43% (13/30) of the informative families;
2) 17 families displayed low positive or negative lod scores;
3) only three families remained non-informative
These results showed that, in this population, an important fraction of ADH (43%) is not due to a defect in the APOB gene. In addition, we looked for the FDB mutations at amino Genetic heterogeneity in hypercholesterolaemia B Saint-Jore et al y acids R3500Q and R3531C in all probands and their spouses, by PCR-mediated site-directed mutagenesis analysis. In the HC24 and HC70 families, probands and several affected members were found positive for the APOB (R3500Q) mutation (data not shown). This direct analysis showed that APOB contribution was at least of 6% (2/33).
Importantly, when combined together these results underscored the existence of a third group of families that showed an exclusion for both genes (HC2, HC6, and HC13, see below). Thus, when considering only the sub-sample of families in which informativity was obtained at both loci, 11% (3/27) of families are unlinked to either locus.
Estimation of the proportions of families associated with LDLR, APOB or 'non-LDLR, non-APOB' gene defects
To estimate the proportion of families linked to either of the candidate genes, we used the HOMOG computer package that analyses the likelihoods computed with the MLINK program. Different analyses were performed using either the LDLR or the APOB gene markers alone (HOMOG), and using both LDLR and APOB gene markers and testing for the evidence of a third family type (HOMOG3R). We did these analyses with different parameters corresponding to different models. Under the first hypothesis, penetrance was considered complete assuming that every individual carrying a mutation was hypercholesterolaemic. In the second model the penetrance was rated at 0.9 for heterozygotes. This second model was investigated to take into account the observed overlap of the distributions of cholesterol levels between affected and unaffected subjects in our sample and also reported by other groups, 1 as well as the single report of incomplete penetrance in a large FH family. 23 The HOMOG tests were highly significant and unsurprisingly confirmed the existence of genetic heterogeneity in the sample. However, they estimated the proportion of families linked to LDLR gene defects at α = 54% and APOB gene defects were estimated = 23% and 20% according to the two different models (penetrance = 1.0 and 0.9, respectively) ( Table 2 ). These results confirmed that familial type IIa hypercholesterolaemia was heterogeneous since LDLR and APOB gene mutations were already identified. However, the contribution of the LDLR locus was much higher than that of the APOB locus. These results also showed that defects in the LDLR and the APOB genes did not account for all cases of Genetic heterogeneity in hypercholesterolaemia y B Saint-Jore et alADH in our sample. Since the HOMOG program performs its statistical analysis testing the existence of linkage between the trait and a single locus, the proportion γ of 'non LDLR/ non APOB' families is more adequately estimated by using the HOMOG3R sub-program which tests for linkage between the trait and two distinct loci under the candidate gene hypothesis. This test confirmed the values obtained previously for the LDLR gene with α = (50%) and slightly reduced the contribution of the APOB gene to 15%. More importantly, it estimated at 35% the proportion (γ) of families linked neither to the LDLR nor the APOB genes. Identical proportions were obtained whatever the model used and both tests were highly significant (P = 0.0001). Since these families originated from two different geographical areas, we tested the homogeneity of our populations by a linkage homogeneity test between samples. The predivided sample test was applied, using the maximum likelihood values obtained for each family sub-sample with the HOMOG3R program. The test showed no statistically significant difference between the 13 families sampled in Paris and the 19 from the other French centres ( 2 2 = 1.14, P < 0.50).
Identification of three 'non-LDLR / non-APOB' families
As the contribution of 'non-LDLR / non-APOB' families was estimated at 35%, we sought to distinctly identify families that would definitively demonstrate the involvement of a third locus. A careful analysis of segregation of markers in our sample disclosed the presence of three families in whom exclusion of the two candidate genes LDLR and APOB could be demonstrated (HC2, HC6 and HC13) (Figure 3) . In family HC2, at the LDLR locus the affected proband transmitted the same allele (H2, A1, T3) to her affected and non-affected sons. At the APOB locus, the proband also transmitted the same allele (T3, S2, V7) to her two sons. A similar analysis performed for family HC6 demonstrates the existence of another non-LDLR / non-APOB family (Figure 3) . Furthermore, these data were supported by cellular and molecular analyses. Genetic exclusions observed for the LDLR gene were confirmed by in vitro studies showing that LDL receptor activity in the probands from both families was equal to that of a normal control subject (data not shown). For the APOB gene, genetic exclusion was confirmed by absence of two APOB R3500Q and R3531C mutations. Finally, genotyping of members at large in the two families identified further recombinants among affected and unaffected subjects and confirmed the exclusion data for both candidate genes (data not shown). In the case of family HC13, samples could not be obtained from affected individuals to evaluate LDL receptor activity.
Discussion
The aim of this study was to evaluate the respective contributions ofLDLR, APOB and other gene defects to dominant type IIa hypercholesterolaemia using genetic linkage analysis and homogeneity tests for linkage in a sample of French families. The families investigated were ascertained through probands that were identified among consecutive patients from the four centres over a period of 2 years. Only nuclear families were studied and, whenever possible, multiplex families were sampled and explored. The exclusion criteria used for the probands were in agreement with generally accepted criteria 41 and rather conservative, since families with subjects presenting triglycerides levels superior to 1.3 mmol/L were excluded. An overlap of the distribution is observed with LDL-cholesterol values ( Figure 2 ). This is due to the unavailability of published reference values of LDLcholesterol. However, when considering the age of the subjects, their status can be unequivocally ascertained.
Results from the HOMOG analyses showed the existence of genetic heterogeneity in the sample. In effect, the hypothesis for linkage heterogeneity (H2 Vs H1) was significant for the LDLR and APOB genes ( Table 2 ). The tests also showed that LDL receptor defects were by far the most common in our sample of ADH families since they were estimated to account for 54% of the cases. Conversely, the contribution of the APOB gene defects was estimated at only 20-30%. There is a discrepancy between these figures and the identification of only two families (HC24 and HC70) who carry the APOB R3500Q mutation. Therefore, the contribution of this mutation was estimated at only 6% in the sample of ADH families. This is in agreement with other European populations as reported by Tybjaerg-Hansen et al, 42 Talmud et al, 43 Miserez et al 44 and Rabès et al. 37 The discrepancy can be explained by the rather large confidence interval associated with the results of the HOMOG tests for the APOB gene markers (Table 2) . However, since the genetic approach we used analyses the possible involvement of a candidate gene and not of a single mutation, our sample could contain a few families carrying still unidentified hypercholesterolaemic mutations of the APOB gene. Careful observation of APOB and LDLR gene haplotypes as well as linkage data revealed that in three families (HC2, HC6, and HC13) the defect was linked to neither of the candidate genes. Therefore to estimate the proportion γ of 'non-LDLR/non-APOB' families, we used a more adequate The new estimated proportions for LDLR and APOB genes were at 55% and 15%, respectively, not statistically different from the estimations previously obtained with the HOMOG tests. LDLR gene defects were still the most common cause of ADH despite the tested hypothesis of existence of three loci associated with the disease. The test confirmed the low contribution of APOB gene defects. Finally, it also showed that γ accounted for 35% of the mutations in our sample, thus second to LDLR gene defects. The results of the genetic analyses were confirmed in two families (HC2 and HC6) by the LDL receptor assay which was normal for both probands (data not shown). Ultracentrifugation analyses of HC2 and HC6 probands' plasma showed a typical type IIa profile with an elevation of LDL particles similar to the pattern observed for patients with an LDLR mutation (data not shown). The clinical and biological findings in these families are identical to those of other type IIa families, but are in general mild and therefore closer to FDB than FH. 17 At the present stage, the identity of the third locus is unknown, but we proved that γ represents a genetically heterogeneous class of defects. In effect, through a genome-wide search, we mapped at 1p34-p32 the disease locus for HC2 and called it 'FH3'. 17 Because of the size of the region on chromosome 1 (8-9 cM), it is impossible to perform admixture tests using anonymous loci markers to evaluate the proportion of families liked to the FH3 locus. However, linkage was excluded between FH3 and the disease in HC6 family. Taken together these results clearly demonstrate that there are at least four loci involved in ADH and that γ is a heterogeneous class of molecular defect. However, because of the numerous proteins, enzymes and receptors involved in cholesterol homeostasis, it is not surprising that there are Identification of these loci will probably unravel new pathogenic mechanisms responsible for hypercholesterolaemia and associated with coronary artery disease. It may also lead to the development of new cholesterol-lowering agents. In conclusion our results obtained in a sample of 33 ADH families show that 1) mutations in the LDLR gene are the most frequent defects;
2) molecular defects associated with the disease are located within at least four loci;
3) together the unknown loci, have a greater contribution to the phenotype than that of the APOB gene.
These results obtained in a small sample of French families await confirmation in other populations and better assessment in larger samples, but do not preclude the identification of the gene involved in the three French 'non-LDLR / non-APOB' ADH families reported.
